Why the study?
Studies frequently exclude heart failure patients with complex psychiatric and medical comorbidities or cognitive impairment, and syndemic frameworks have not been applied to their complex psychosocial problems.
Do psychosocial syndemics and multimorbidity affect readmissions, mortality, self-care, and global health in patients with heart failure?
Do psychosocial syndemics and multimorbidity affect readmissions, mortality, self-care, and global health in patients with heart failure?
This study aims to identify how combinations of psychiatric and medical comorbidities affect outcomes such as readmissions, mortality, and self-care in patients with heart failure.
Heart failure (HF) is a common cause of hospitalization and mortality in older adults. HF is almost always embedded within a larger pattern of multimorbidity, yet many studies exclude patients with complex psychiatric and medical comorbidities or cognitive impairment. This has left significant gaps in research on the problems and treatment of patients with HF. In addition, HF is only one of multiple challenges facing patients with multimorbidity, stressful socioeconomic circumstances, and psychosocial problems. The purpose of this study is to identify combinations of comorbidities and health disparities that may affect HF outcomes and require different mixtures of medical, psychological, and social services to address. The syndemics framework has yielded important insights into other disorders such as HIV/AIDS, but it has not been applied to the complex psychosocial problems of patients with HF. The multimorbidity framework is an alternative approach for investigating the effects of multiple comorbidities on health outcomes. The specific aims are: (1) to determine the coprevalence of psychiatric and medical comorbidities in patients with HF (n = 535); (2) to determine whether coprevalent comorbidities have synergistic effects on readmissions, mortality, self-care, and global health; (3) to identify vulnerable subpopulations of patients with HF who have high coprevalences of syndemic comorbidities; (4) to determine the extent to which syndemic comorbidities explain adverse HF outcomes in vulnerable subgroups of patients with HF; and (5) to determine the effects of multimorbidity on readmissions, mortality, self-care, and global health. Study Registration: clinicaltrials.gov identifier: NCT04637776.
No takes yet. Share an insight, caveat, or question.
Freedland et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: